Cardiac care has always been a numbers game, beats per minute, ejection fractions, diagnostic accuracy. But when you see Peerbridge Health raise $7.18 million in a fresh filing on its way to an $8 million round, those numbers start to sound more like music than math. Because this isn’t just capital flowing in, it’s proof that technology, medicine, and stubborn persistence are finally syncing into one rhythm that matters: saving lives before the heart gives out.
Founded in 2012 by Dr. Angelo Acquista, M.D., Peerbridge didn’t come out of a Stanford lab or a hackathon weekend. It came from a living room where Dr. Angelo Acquista watched his father wrestle with tangled wires and outdated monitors, and decided enough was enough. That spark turned into Peerbridge Cor, a three-lead, two-channel wireless AECG patch that doesn’t just collect data, it translates it into hospital-grade diagnostics powered by explainable AI. In other words, it’s a patch with the precision of a cardiology lab strapped to your chest.
Fast-forward to today and the company sits inside 3 Columbus Circle in New York City with an office in Nashville, carrying the kind of swagger only earned through FDA clearance, nine U.S. patents, and clinical trials that clocked a 95.7 percent accuracy rate in detecting heart failure. That’s not theory, that’s proof. It’s why Peerbridge Health took home the 2025 MedTech Breakthrough Award for Best New Technology Solution for Cardiology. Awards don’t keep patients alive, but accuracy and speed do, and Peerbridge delivers reports in under thirty minutes. That’s the difference between an ER admission and a safe night at home.
Leadership matters in this story too. Chris Darland, CEO, took the reins in 2023 after a career managing billions in finance at Ecolab and GE, and he’s bringing operational discipline to a space known for its chaos. Dr. Angelo Acquista still drives the medical vision, while CTO Sandeep Gulati, Ph.D., shapes the AI and device architecture. Add National Clinical Director Dale DuBois and Director of Regulatory and Quality Adam Viitala, and you have a team that knows how to walk the tightrope between innovation and compliance.
On the cap table, the roll call is just as strong. HealthX Ventures and Mendota Venture Capital have been steady backers. HeartX Accelerator and Mayo Clinic Platform Accelerate pushed early validation. Kinled Holding, Northwell Health, Fine Day Ventures, and Deerfield Management added credibility and capital. This latest $7.18 million shows those relationships are still paying off, and that investors see a clear path for commercialization, especially with the upcoming Cor MDx device powered by AT&T’s IoT connectivity and Google Cloud through SADA.
The opportunity is massive. Six million Americans live with heart failure, with a million new diagnoses each year. Peerbridge Health isn’t chasing vanity metrics, it’s targeting one of the most expensive and deadly chronic conditions in the country. If they nail national deployment, hospitals won’t just get better data, they’ll get relief from readmission penalties, overburdened cardiology units, and patients who deserve monitoring that actually works.
What makes this raise different is that it’s not about growth for growth’s sake. It’s about scaling technology that reduces cost, increases accuracy, and does it in a form factor patients will actually wear. Peerbridge is building hospital-grade diagnostics into living rooms, nursing homes, and rural clinics. That’s more than innovation, it’s inevitability.
